journal
Journals Drug Design, Development and T...

Drug Design, Development and Therapy

https://read.qxmd.com/read/38618283/dexmedetomidine-prolongs-lidocaine-intravenous-regional-anesthesia-in-rats-by-blocking-the-hyperpolarization-activated-cation-current
#1
JOURNAL ARTICLE
Tongtong Zhang, Xincheng Liao, Yuzhi Chen, Xinru Shu, Deshan Liu, Yusheng Yao
PURPOSE: Intravenous regional anesthesia (IVRA) using lidocaine provides effective localized analgesia but its duration is limited. The mechanism by which dexmedetomidine enhances lidocaine IVRA is unclear but may involve modulation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. MATERIALS AND METHODS: Lidocaine IVRA with varying dexmedetomidine concentrations was performed in the tails of Sprague-Dawley rats. Tail-flick and tail-clamping tests assessed IVRA analgesia and anesthesia efficacy and duration...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38618282/the-promise-of-therapeutic-psilocybin-an-evaluation-of-the-134-clinical-trials-54-potential-indications-and-0-marketing-approvals-on-clinicaltrials-gov
#2
JOURNAL ARTICLE
Sarah A Norring, Michael G Spigarelli
INTRODUCTION: Psilocybin, a tryptamine psychedelic, has been touted in the media both historically and recently as a potential game-changing mental health therapeutic. ClinicalTrials.gov has over one hundred and thirty psilocybin clinical trials listed covering the last twenty years. The single most important aspect of any therapeutic is to gain approval for marketing and thus enter the real-world phase of development. A typical new chemical entity progresses from inception to US Food and Drug Administration (FDA) approval in approximately 12 years and seeks approval for a single indication...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38618281/synthesis-and-anti-diabetic-activity-of-an-8-purine-derivative-as-a-novel-dpp-4-inhibitor-in-obese-diabetic-z%C3%A3-cker-rats
#3
JOURNAL ARTICLE
Meriem Chayah, Angélica Luque-González, Verónica Gómez-Pérez, Diego Salagre, Amjad Al-Shdaifat, Joaquín María Campos, Ana Conejo-García, Ahmad Agil
Type 2 diabetes mellitus (T2DM) is one of the world's principal metabolic diseases characterized by chronic hyperglycemia. The gut incretin hormones, glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), which has been proposed as a new treatment for T2DM, are extensively metabolized by Dipeptidyl peptidase 4 (DPP-4). Inhibitors of DPP-4 block the degradation of GLP-1 and GIP and may increase their natural circulating levels, favoring glycemic control in T2DM. A novel and potent selective inhibitor of DPP-4 with an 8-purine derived structure ( 1 ) has been developed and tested in vitro and in vivo in Zücker obese diabetic fatty (ZDF) rats, an experimental model of the metabolic syndrome and T2DM to assess the inhibitory activity using vildagliptin as reference standard...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38618280/unveiling-the-mechanism-of-the-chaishao-shugan-formula-against-triple-negative-breast-cancer
#4
JOURNAL ARTICLE
Teng Fan, Yuanyuan Huang, Zeyu Liu, Jinsheng Huang, Bin Ke, Yuming Rong, Huijuan Qiu, Bei Zhang
BACKGROUND: The ChaiShao Shugan Formula (CSSGF) is a traditional Chinese medicine formula with recently identified therapeutic value in triple-negative breast cancer (TNBC). This study aimed to elucidate the underlying mechanism of CSSGF in TNBC treatment. METHODS: TNBC targets were analyzed using R and data were from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The major ingredients and related protein targets of CSSGF were explored via the Traditional Chinese Medicine Systems Pharmacology database, and an ingredient-target network was constructed via Cytoscape to identify hub genes...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38618279/outcome-of-darunavir-cobicistat-based-regimens-in-hiv-infected-people-who-have-experienced-virological-failure
#5
JOURNAL ARTICLE
Francesca Alberton, Laura Galli, Riccardo Lolatto, Caterina Candela, Nicola Gianotti, Matteo Chiurlo, Martina Ranzenigo, Martina Strano, Alessia Uglietti, Antonella Castagna
OBJECTIVE: To evaluate the virological outcome of darunavir-cobicistat (DRVc)-based regimens in adults living with HIV who had experienced virological failure (VF) on any previous drug combination. METHODS: This was a retrospective cohort study (CSLHIV Cohort) of adults living with HIV who started a DRVc-based regimen with HIV-RNA >50 copies/mL after VF on any previous drug combination. Data on demographics, antiretroviral treatment since HIV diagnosis, and immunological and metabolic parameters from baseline (start of DRVc) to 48 weeks were analyzed in order to assess the cumulative proportion of those who achieved virological success (VS), defined as at least one instance of HIV-RNA <50 copies/mL within 12 months from baseline...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38585257/mapping-the-research-of-ferroptosis-in-parkinson-s-disease-from-2013-to-2023-a-scientometric-review
#6
REVIEW
Yingfan Chen, Zhenhui Wu, Shaodan Li, Qi Chen, Liang Wang, Xiaorong Qi, Chujiao Tian, Minghui Yang
METHODS: Related studies on PD and ferroptosis were searched in Web of Science Core Collection (WOSCC) from inception to 2023. VOSviewer, CiteSpace, RStudio, and Scimago Graphica were employed as bibliometric analysis tools to generate network maps about the collaborations between authors, countries, and institutions and to visualize the co-occurrence and trends of co-cited references and keywords. RESULTS: A total of 160 original articles and reviews related to PD and ferroptosis were retrieved, produced by from 958 authors from 162 institutions...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38585256/exploring-the-median-effective-dose-of-ciprofol-for-anesthesia-induction-in-elderly-patients-impact-of-frailty-on-ed-50
#7
Jingjing Yuan, Zenghui Liang, Muhoza Bertrand Geoffrey, Yanle Xie, Shuhan Chen, Jing Liu, Yuzhong Xia, Huixin Li, Yanling Zhao, Yuanyuan Mao, Na Xing, Jianjun Yang, Zhongyu Wang, Fei Xing
PURPOSE: Explore the median effective dose of ciprofol for inducing loss of consciousness in elderly patients and investigate how frailty influences the ED50 of ciprofol in elderly patients. PATIENTS AND METHODS: A total of 26 non-frail patients and 28 frail patients aged 65-78 years, with BMI ranging from 15 to 28 kg/m2 , and classified as ASA grade II or III were selected. Patients were divided into two groups according to frailty: non-frail patients (CFS<4), frail patients (CFS≥4)...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38585255/molecular-modeling-synthesis-and-antihyperglycemic-activity-of-the-new-benzimidazole-derivatives-imidazoline-receptor-agonists
#8
JOURNAL ARTICLE
Artur Martynov, Boris Farber, Tatyana Bomko, Daniel L Beckles, Ilya Kleyn
INTRODUCTION: The paper presents the results of a study on the first synthesized benzimidazole derivatives obtained from labile nature carboxylic acids. The synthesis conditions of these substances were studied, their structure was proved, and some components were found to have sugar-reducing activity on the model of alloxan diabetes in rats. METHODS: The study used molecular modeling methods such as docking based on the evolutionary model (igemdock), RP_HPLC method to monitor the synthesis reaction, and 1H NMR and 13C NMR, and other methods of organic chemistry to confirm the structures of synthesized substances...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38585254/updated-evaluation-of-agalsidase-alfa-enzyme-replacement-therapy-for-patients-with-fabry-disease-insights-from-real-world-data
#9
REVIEW
Sandro Feriozzi, Cristina Chimenti, Ricardo Claudio Reisin
The clinical use of agalsidase alfa as enzyme replacement therapy (ERT) for Fabry disease (FD) has spread since 2001, and a large body of evidence of its effectiveness has been collected. This review presents the clinical and laboratory results achieved with agalsidase alfa, which has been published in the literature. Agalsidase alfa infusion slows down or stops the progression of renal damage, expressed by reduction or stabilization of the annual decline of the glomerular filtration rate; yearly decrease of glomerular filtration rate (slope) sometimes is reduced until its stabilization...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38585253/forsythoside-b-mitigates-monocrotaline-induced-pulmonary-arterial-hypertension-via-blocking-the-nf-%C3%AE%C2%BAb-signaling-pathway-to-attenuate-vascular-remodeling-letter
#10
JOURNAL ARTICLE
Agriani Dini Pasiana, Hasta Handayani Idrus, Istianah Purnamasari
No abstract text is available yet for this article.
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38567255/revolutionizing-stroke-recovery-unveiling-the-promise-of-stem-cell-therapy
#11
REVIEW
Leonidas D Panos, Panagiotis Bargiotas, Marcel Arnold, Georgios Hadjigeorgiou, Georgios D Panos
Stem cells, renowned for their unique regenerative capabilities, present significant hope in treating stroke, a major cause of disability globally. This review offers a detailed analysis of stem cell applications in stroke (ischemic and hemorrhagic) recovery. It examines therapies based on autologous (patient-derived), allogeneic (donor-derived), and Granulocyte-Colony Stimulating Factor (G-CSF) based stem cells, focusing on cell types such as Mesenchymal Stem/Stromal Cells (MSCs), Bone Marrow Mononuclear Stem Cells (BMMSCs), and Neural Stem/Progenitor Cells (NSCs)...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38567254/the-emerging-roles-of-nanocarrier-drug-delivery-system-in-treatment-of-intervertebral-disc-degeneration-current-knowledge-hot-spots-challenges-and-future-perspectives
#12
REVIEW
Yunxiang Hu, Rui Yang, Sanmao Liu, Zefeng Song, Hong Wang
Low back pain (LBP) is a common condition that has substantial consequences on individuals and society, both socially and economically. The primary contributor to LBP is often identified as intervertebral disc degeneration (IVDD), which worsens and leads to significant spinal problems. The conventional treatment approach for IVDD involves physiotherapy, drug therapy for pain management, and, in severe cases, surgery. However, none of these treatments address the underlying cause of the condition, meaning that they cannot fundamentally reverse IVDD or restore the mechanical function of the spine...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38562520/neurophysiological-characteristics-in-type-ii-and-type-iii-5q-spinal-muscular-atrophy-patients-impact-of-nusinersen-treatment
#13
JOURNAL ARTICLE
Dan Li, Na Sun, Li Xiang, Jingjie Liu, Xueying Wang, Lin Yang, Shaoping Huang
OBJECTIVE: This study aimed to observe the neurophysiological characteristics of type II and type III 5q spinal muscular atrophy (SMA) patients and the changes in peripheral motor nerve electrophysiology after Nusinersen treatment, as well as the influencing factors. METHODS: This single-center retrospective case-control study collected clinical data and peripheral motor nerve CMAP parameters from 42 5qSMA patients and 42 healthy controls at the Second Affiliated Hospital of Xi'an Jiaotong University (January 2021 to December 2022)...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38562519/the-potential-of-exosomes-for-osteoporosis-treatment-a-review
#14
REVIEW
Yinxi He, Yanxia Chen
As a continuous process comprising bone resorption and formation, bone remodeling, plays an essential role in maintaining the balance of bone metabolism. One type of metabolic osteopathy is osteoporosis, which is defined by low bone mass and deteriorating bone microstructure. Osteoporosis patients are more likely to experience frequent osteoporotic fractures, which makes osteoporosis prevention and treatment crucial. A growing body of research has revealed that exosomes, which are homogenous vesicles released by most cell types, play a major role in mediating a number of pathophysiological processes, including osteoporosis...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38562518/the-safety-and-efficacy-of-remimazolam-compared-to-dexmedetomidine-for-awake-tracheal-intubation-by-flexible-bronchoscopy-a-randomized-double-blind-controlled-trial
#15
RANDOMIZED CONTROLLED TRIAL
Qiumiao Chen, Bin Qin, Manqing Zhang, Yumei Zhou, Xiaotong Shi, Yubo Xie
BACKGROUND: Remimazolam is a novel ultra-short-acting benzodiazepine sedative that has the potential to be an alternative for procedural sedation due to its rapid sedation and recovery, no accumulation effect, stable hemodynamics, minimal respiratory depression, anterograde amnesia effect, and specific antagonist. Here, we aimed to compare the safety and efficacy of remimazolam with dexmedetomidine for awake tracheal intubation by flexible bronchoscopy (ATI-FB). METHODS: Ninety patients scheduled for ATI-FB were randomly divided into three groups, each consisting of 30 cases: dexmedetomidine 0...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38560524/the-impact-of-baohuoside-i-on-the-metabolism-of-tofacitinib-in-rats
#16
JOURNAL ARTICLE
Yaru Shi, Zebei Lu, Wei Song, Yu Wang, Quan Zhou, Peiwu Geng, Yunfang Zhou, Shuanghu Wang, Aixia Han
PURPOSE: To study the potential drug-drug interactions between tofacitinib and baohuoside I and to provide the scientific basis for rational use of them in clinical practice. METHODS: A total of eighteen Sprague-Dawley rats were randomly divided into three groups: control group, single-dose group (receiving a single dose of 20 mg/kg of baohuoside I), and multi-dose group (receiving multiple doses of baohuoside I for 7 days). On the seventh day, each rat was orally administered with 10 mg/kg of tofacitinib 30 minutes after giving baohuoside I or vehicle...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38560523/effect-of-intraoperative-infusion-magnesium-sulfate-infusion-on-postoperative-quality-of-recovery-in-patients-undergoing-total-knee-arthroplasty-a-prospective-double-blind-randomized-controlled-trial
#17
RANDOMIZED CONTROLLED TRIAL
Hai Xu, Conghui Hao, Xinxin Wang, Jingjing Du, Tianyu Zhang, Xiaobao Zhang
BACKGROUND: Magnesium sulfate, an intravenous adjuvant, has recently attracted immense attention in multimodal analgesia. Previous studies confirmed the crucial role of magnesium sulfate in postoperative pain and nociceptive hypersensitivity. However, the effect of magnesium sulfate in multimodal analgesia on the quality of recovery (QoR) for elderly patients has not been thoroughly studied. Therefore, the present experiment aimed to investigate the effect of continuous intravenous magnesium sulfate on the quality of postoperative recovery in elderly patients undergoing total knee arthroplasty (TKA)...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38560522/a-review-of-dupilumab-in-the-treatment-of-atopic-dermatitis-in-infants-and-children
#18
REVIEW
Mingyue Wang, Xing-Hua Gao, Li Zhang
Atopic dermatitis (AD), a common pruritic and chronic inflammatory skin disease, has a major impact on a patient's quality of life. It is characterized by dry, itchy, and eczema-like rashes. AD is more prevalent in young children and has been linked to a variety of other allergy disorders. Traditional drug therapy has certain limitations for treating young children with AD. However, biologics have good clinical application prospects in the medical treatment of young patients. Dupilumab, a fully human monoclonal antibody, specifically binds to the IL-4 Rα subunit, inhibiting IL-4 and IL-13 signaling and blocking the occurrence of type 2 inflammatory response...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38545432/intracranial-efficacy-of-pyrotinib-and-capecitabine-combination-therapy-in-her2-positive-breast-cancer-with-brain-metastases
#19
JOURNAL ARTICLE
Congcong Wang, Jinyu Xiang, Qingyu Zhang, Jing Li, Yanqing Liu, Jiannan Liu
AIM: Approximately 50% of patients diagnosed with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (BC) are estimated to develop brain metastases (BMs). This study was aimed to assess the intracranial efficacy and survival benefits of pyrotinib and capecitabine combination therapy in the treatment of BMs in patients with HER2-positive BC. METHODS: A total of 56 HER2-positive BC patients with BMs were treated with 400 mg pyrotinib once daily along with 1000 mg/m2 capecitabine twice daily for 14 days in 21-day cycles...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38533429/harmonising-iv-oxycodone-with-paediatric-perioperative-medications-a-compatibility-study-through-y-type-connectors
#20
JOURNAL ARTICLE
Souha H Youssef, Alka Garg, Yunmei Song, Nicole E Wylie, Sanjay Garg
PURPOSE: Co-administering multiple intravenous (IV) agents via Y-connectors is a common practice in hospitalised and fasting surgical patients. However, there is a lack of reliable data confirming the physical compatibility of some combinations including IV oxycodone, a drug that is gaining increasing popularity in the perioperative period. Concern regarding physical drug incompatibilities precludes concurrent coadministration with other common drugs through a single lumen. This can result in the cessation of infusions to allow the administration of other medications, resulting in exacerbation of acute pain...
2024: Drug Design, Development and Therapy
journal
journal
42019
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.